Affordable Access

Access to the full text

A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries

Authors
  • Saida, Takahiko1
  • Yamamura, Takashi2
  • Kondo, Takayuki3
  • Yun, Jang4
  • Yang, Minhua4
  • Li, Jie4, 5
  • Mahadavan, Lalitha4, 6
  • Zhu, Bing4
  • Sheikh, Sarah I.4
  • 1 Kyoto Min-iren Central Hospital, Kansai Multiple Sclerosis Centre, Nishinokyo-Kasuga-cho 16-44-409, Nakakyo-ku, Kyoto, 604-8453, Japan , Nakakyo-ku, Kyoto (Japan)
  • 2 National Center Hospital, NCNP, Tokyo, Japan , Tokyo (Japan)
  • 3 Kansai Medical University Medical Center, Osaka, Japan , Osaka (Japan)
  • 4 Biogen, Cambridge, MA, USA , Cambridge (United States)
  • 5 Sanofi, Cambridge, MA, USA , Cambridge (United States)
  • 6 Faculty of Pharmaceutical Medicine, London, UK , London (United Kingdom)
Type
Published Article
Journal
BMC Neurology
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jan 07, 2019
Volume
19
Issue
1
Identifiers
DOI: 10.1186/s12883-018-1220-3
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundDelayed-release dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in phase 2 and 3 studies that enrolled predominantly white patients with relapsing-remitting multiple sclerosis (RRMS). In this study (APEX, Part I), we evaluated the efficacy/safety outcomes of DMF in a predominantly East Asian population of patients with RRMS.MethodsIn this 24-week, randomized, double-blind, placebo-controlled phase 3 study, 225 patients, 142 of which were East Asian (63.4%), were enrolled: Japan (n = 114), South Korea (n = 20), Taiwan (n = 8), the Czech Republic (n = 42), and Poland (n = 40). Key exclusion criteria included diagnosis of neuromyelitis optica spectrum disorder. Stratified by country, patients were randomized 1:1 to receive DMF 240 mg twice daily or placebo. Clinical assessments, including neurological examination and EDSS scoring, were conducted at baseline and at weeks 12 and 24.ResultsA total of 213 patients (95.1%) completed the study. From weeks 12 – 24, the total number of new gadolinium-enhancing (Gd+) lesions was reduced by 84% (p < 0.0001) in DMF compared with placebo. For the secondary endpoint, from baseline to week 24, the total number of new Gd+ lesions was reduced by 75% and the mean number of new/newly enlarging T2 hyperintense lesions was reduced by 63% (both p < 0.0001). Flushing and flushing-related symptoms, and gastrointestinal events were adverse events related to DMF treatment. Efficacy and safety results in the Japanese subgroup and the East Asian subgroup (which included patients from Japan, Taiwan, and South Korea) were consistent with the overall study population.ConclusionThe strong efficacy and favorable benefit-risk profile of DMF extends to Japanese, and more broadly, East Asian patients with RRMS.Trial registrationThis trial is registered on ClinicalTrials.gov (identifier: NCT01838668), April 20, 2013 (retrospectively registered). The registration can be found at the following URL: https://clinicaltrials.gov/ct2/show/NCT01838668

Report this publication

Statistics

Seen <100 times